Eastern Bank Grows Stake in Hologic, Inc. (HOLX)

Eastern Bank increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.1% in the 4th quarter, Holdings Channel reports. The firm owned 266,344 shares of the medical equipment provider’s stock after buying an additional 2,862 shares during the period. Eastern Bank’s holdings in Hologic were worth $11,386,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Koch Industries Inc. increased its holdings in Hologic by 15,554.1% during the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after buying an additional 1,142,138 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in Hologic by 8.1% during the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock valued at $2,593,000 after buying an additional 4,300 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its holdings in Hologic by 1.4% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock valued at $8,975,000 after buying an additional 3,391 shares during the last quarter. Cipher Capital LP increased its holdings in Hologic by 57.9% during the third quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock valued at $4,317,000 after buying an additional 43,146 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Hologic by 15.5% during the third quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock valued at $10,458,000 after buying an additional 38,283 shares during the last quarter. 97.24% of the stock is owned by hedge funds and other institutional investors.

Hologic, Inc. (NASDAQ:HOLX) traded down $0.39 on Monday, hitting $43.46. 4,355,400 shares of the company’s stock were exchanged, compared to its average volume of 2,875,292. The company has a market capitalization of $11,890.00, a price-to-earnings ratio of 16.46, a P/E/G ratio of 2.06 and a beta of 0.95. Hologic, Inc. has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 earnings per share. equities research analysts expect that Hologic, Inc. will post 2.16 EPS for the current year.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,099 shares of company stock valued at $487,223. Company insiders own 0.79% of the company’s stock.

A number of analysts have commented on the stock. Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a report on Friday. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 target price (up from $48.00) on shares of Hologic in a report on Tuesday, January 9th. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a research report on Thursday, January 4th. Finally, Evercore ISI initiated coverage on shares of Hologic in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $50.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $48.79.

ILLEGAL ACTIVITY WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/22/eastern-bank-grows-stake-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit